The following video is part of our "Motley Fool Conversations" series in which health-care editor and analyst David Williamson and industrials editor and analyst Brendan Byrnes discuss topics across the investing world.

In today's edition, David and Brendan discuss popular biotech Exelixis. They review the two deals the company brokered in recent weeks and how they will impact Exelixis as it tries to advance cabozantinib in 2012.

Brendan Byrnes does not own shares of the companies listed above. David Williamson owns shares of Johnson & Johnson. The Motley Fool owns shares of Exelixis and Johnson & Johnson. Motley Fool newsletter services recommend Exelixis and Gilead Sciences. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.